Drybench Pipeline runs in your browser and needs JavaScript. Turn JavaScript on for this site, or read about the app on its product page. Read about the app

Drybench Pipeline

Trials for any condition from ClinicalTrials.gov, US approvals from openFDA, and the historical odds of getting there.

v0.1.0 · Preview

Loading the drug pipeline explorer…

Inspector

Sources

Where the data in this workspace comes from, and the licence each source is used under.

ClinicalTrials.gov API v2 (opens in a new tab)
ClinicalTrials.gov Terms and Conditions: no charge; attribute the source, keep the data current, show the processing date and state modifications (the data carry copyright outside the US)
Live trial records: phase, status, dates, sponsor, enrolment, interventions and stop reasons
openFDA drug label, Drugs@FDA and NDC endpoints (opens in a new tab)
CC0 1.0
US-approved products whose label indications mention the condition, with sponsor, approval date and marketing status
BIO, Informa Pharma Intelligence and QLS Advisors: Clinical Development Success Rates 2011–2020 (February 2021) (opens in a new tab)
No reuse licence; © BIO, QLS Advisors and Informa UK Ltd 2021. Figures quoted with attribution
Phase success rates, likelihood of approval by area and modality, and phase durations (Figures 2, 5b, 6, 7, 8b, 10b, 17)
WHO: Use of stems in the selection of INN for pharmaceutical substances, 2024 (opens in a new tab)
CC BY-NC-SA 3.0 IGO (reference only)
The naming stems behind the modality classifier, checked stem by stem against Part II B. The short class labels are the tool's own; a few are standard class names (such as tyrosine kinase inhibitor) that the book also uses